Get the Stockscreener App
54.58
5.53%
2.86
Alkermes Plc stock is traded at $54.58, with a volume of 1.65M.
It is up +5.53% in the last 24 hours and up +32.09% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$51.72
Open:
$52.5
24h Volume:
1.65M
Relative Volume:
0.67
Market Cap:
$9.10B
Revenue:
$1.56B
Net Income/Loss:
$152.72M
P/E Ratio:
60.68
EPS:
0.8994
Net Cash Flow:
$221.80M
1W Performance:
+3.31%
1M Performance:
+32.09%
6M Performance:
+93.14%
1Y Performance:
+88.21%
1-Day Range:
$51.72
$54.69
1-Week Range:
$50.96
$55.27
52-Week Range:
$25.16
$55.27
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
54.58 | 8.73B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
16.77 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.82 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.64 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.80 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
555.91 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes (ALKS) R&D chief exercises 5,000 options and sells 9,000 shares - Stock Titan
Alkermes (ALKS) shows multiple 9,000-share insider sales, exercise and vesting - Stock Titan
ALKSAlkermes plc Latest SEC Filings - Finviz
Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 AdditionWhat's Changed - Yahoo Finance
A Look at Alkermes PLC (ALKS) After 4.8% Decline -- GF Value $31 - GuruFocus
Alkermes plummets on mid-stage Alixorexton data for narcolepsy - MSN
ALKS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
ALKS Downgraded by B of A Securities -- Rating Changed to Underp - GuruFocus
BofA downgrades Alkermes stock rating on valuation concerns By Investing.com - Investing.com Australia
BofA downgrades Alkermes stock rating on valuation concerns - Investing.com
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Enterprise value to EBIT forward of Alkermes plc – NASDAQ:ALKS - TradingView
Press Release: Alkermes to Report First Quarter Financial Results on May 5, 2026 - Moomoo
Price to sales forward of Alkermes plc – NASDAQ:ALKS - TradingView
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda - BioPharma Dive
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI
Alkermes Public Limited Company Actuals & Estimates (NASDAQ:ALKS) - TradingView
ALKS Forecast — Price Target — Prediction for 2027 - TradingView
Alkermes stock hits 52-week high at 51.77 USD By Investing.com - Investing.com South Africa
Alkermes stock hits 52-week high at 51.77 USD - Investing.com
Liquidity Mapping Around (ALKS) Price Events - Stock Traders Daily
Alkermes Jumps 6.9% After Needham Maintains Buy - AlphaStreet
ALKS Maintained by Needham -- Price Target Raised to $61.00 - GuruFocus
Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tel - GuruFocus
ALKS Maintained by TD Cowen -- Price Target Raised to $50 - GuruFocus
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes plc (ALKS) Stock Analysis: Navigating Growth in Biopharmaceuticals with a 4.88% Upside - DirectorsTalk Interviews
Alkermes presents detailed positive results from Vibrance-2 phase 2 study of Alixorexton in adults with narcolepsy type 2 at SLEEP 2026 - MSN
Alkermes announces orphan drug designations for Alixorexton in the US and Europe - MSN
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS) - Seeking Alpha
Did Positive Vibrance-2 Data for Alixorexton Just Shift Alkermes' (ALKS) Investment Narrative? - simplywall.st
Alkermes stock hits 52-week high at 45.76 USD By Investing.com - Investing.com India
Alkermes stock hits 52-week high at 45.76 USD - Investing.com
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Alkermes (ALKS): Piper Sandler Lowers Price Target, Maintains Ov - GuruFocus
Alkermes (ALKS) Study Results Highlight Potential Benefits for N - GuruFocus
Needham raises Alkermes stock price target on narcolepsy drug data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Alkermes stock rating on trial data By Investing.com - Investing.com South Africa
Needham raises Alkermes stock price target on narcolepsy drug data - Investing.com
H.C. Wainwright reiterates Alkermes stock rating on trial data - Investing.com
ALKS Maintains Buy Rating by Needham -- Price Target Raised to $54.00 - GuruFocus
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 - BioSpace
Alkermes Plc (ALKS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alkermes Plc (ALKS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alkermes Plc (ALKS) Institutional Confidence - TradingKey
Alkermes Plc (ALKS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Jul 01 '26 |
Sale |
51.51 |
9,000 |
463,621 |
73,389 |
2.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):